187 related articles for article (PubMed ID: 28792260)
1. Phase-I and randomized phase-II trial of panobinostat in combination with ICE (ifosfamide, carboplatin, etoposide) in relapsed or refractory classical Hodgkin lymphoma.
Hu B; Younes A; Westin JR; Turturro F; Claret L; Feng L; Fowler N; Neelapu S; Romaguera J; Hagemeister FB; Rodriguez MA; Samaniego F; Fayad LE; Copeland AR; Nastoupil LJ; Nieto Y; Fanale MA; Oki Y
Leuk Lymphoma; 2018 Apr; 59(4):863-870. PubMed ID: 28792260
[TBL] [Abstract][Full Text] [Related]
2. Dose-dense brentuximab vedotin plus ifosfamide, carboplatin, and etoposide for second-line treatment of relapsed or refractory classical Hodgkin lymphoma: a single centre, phase 1/2 study.
Lynch RC; Cassaday RD; Smith SD; Fromm JR; Cowan AJ; Warren EH; Shadman MS; Shustov A; Till BG; Ujjani CS; Libby EN; Philip M; Coye H; Martino CN; Bhark SL; Morris K; Rasmussen H; Behnia S; Voutsinas J; Gopal AK
Lancet Haematol; 2021 Aug; 8(8):e562-e571. PubMed ID: 34329577
[TBL] [Abstract][Full Text] [Related]
3. Outpatient fractionated ifosfamide, carboplatin and etoposide as salvage therapy in relapsed and refractory non-Hodgkin's and Hodgkin's lymphoma.
Hertzberg MS; Crombie C; Benson W; Taper J; Gottlieb D; Bradstock KF
Ann Oncol; 2006 May; 17 Suppl 4():iv25-30. PubMed ID: 16702181
[TBL] [Abstract][Full Text] [Related]
4. Phase I study of panobinostat plus everolimus in patients with relapsed or refractory lymphoma.
Oki Y; Buglio D; Fanale M; Fayad L; Copeland A; Romaguera J; Kwak LW; Pro B; de Castro Faria S; Neelapu S; Fowler N; Hagemeister F; Zhang J; Zhou S; Feng L; Younes A
Clin Cancer Res; 2013 Dec; 19(24):6882-90. PubMed ID: 24097867
[TBL] [Abstract][Full Text] [Related]
5. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
Hagemeister FB
Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
[TBL] [Abstract][Full Text] [Related]
6. Outcome of pediatric recurrent and refractory malignant solid tumors following ifosfamide/carboplatin/etoposide (ICE): A phase II study in a pediatric oncology centre in Brazil.
Loss JF; Santos PP; Leone LD; Brunetto AL
Pediatr Blood Cancer; 2004 Feb; 42(2):139-44. PubMed ID: 14752877
[TBL] [Abstract][Full Text] [Related]
7. Comparison of ICE (ifosfamide-carboplatin-etoposide) versus DHAP (cytosine arabinoside-cisplatin-dexamethasone) as salvage chemotherapy in patients with relapsed or refractory lymphoma.
Abali H; Urün Y; Oksüzoğlu B; Budakoğlu B; Yildirim N; Güler T; Ozet G; Zengin N
Cancer Invest; 2008 May; 26(4):401-6. PubMed ID: 18443961
[TBL] [Abstract][Full Text] [Related]
8. Final results of brentuximab vedotin combined with ifosfamide-carboplatin-etoposide in first refractory/relapsed Hodgkin lymphoma: a lymphoma study association phase I/II study.
Stamatoullas A; Ghesquières H; Feugier P; André M; Le Bras F; Gac AC; Borel C; Gastinne T; Quittet P; Morschhauser F; Ribrag V; Guidez S; Nicolas-Virelizier E; Berriolo-Riedinger A; Vander Borght T; Edeline V; Brice P
Leuk Lymphoma; 2022 Dec; 63(13):3063-3071. PubMed ID: 35975738
[TBL] [Abstract][Full Text] [Related]
9. Sequential high-dose ifosfamide, carboplatin and etoposide with rituximab for relapsed Hodgkin and large B-cell non-Hodgkin lymphoma: increased toxicity without improvement in progression-free survival.
Shea TC; Beaven AW; Moore DT; Serody JS; Gabriel DA; Chao N; Gockerman JP; Garcia RA; Rizzieri DA
Leuk Lymphoma; 2009 May; 50(5):741-8. PubMed ID: 19358012
[TBL] [Abstract][Full Text] [Related]
10. Gemcitabine, cisplatin, and dexamethasone and ifosfamide, carboplatin, and etoposide regimens have similar efficacy as salvage treatment for relapsed/refractory aggressive lymphoma: A retrospectively comparative study.
Mi M; Zhang C; Liu Z; Wang Y; Li J; Zhang L
Medicine (Baltimore); 2020 Dec; 99(49):e23412. PubMed ID: 33285732
[TBL] [Abstract][Full Text] [Related]
11. A Phase I/II Trial of Panobinostat in Combination With Lenalidomide in Patients With Relapsed or Refractory Hodgkin Lymphoma.
Maly JJ; Christian BA; Zhu X; Wei L; Sexton JL; Jaglowski SM; Devine SM; Fehniger TA; Wagner-Johnston ND; Phelps MA; Bartlett NL; Blum KA
Clin Lymphoma Myeloma Leuk; 2017 Jun; 17(6):347-353. PubMed ID: 28622959
[TBL] [Abstract][Full Text] [Related]
12. A phase I study of panobinostat in combination with ICE (Ifosfamide, Carboplatin and Etoposide) in patients with relapsed or refractory classical Hodgkin lymphoma (cHL).
Clin Adv Hematol Oncol; 2014 Feb; 12(2 Suppl 6):5-6. PubMed ID: 24870872
[No Abstract] [Full Text] [Related]
13. Augmented ICE in Patients With Poor-Risk Refractory and Relapsed Lymphomas.
Loo S; Lim A; Lee ST; Grigg A
Clin Lymphoma Myeloma Leuk; 2023 Mar; 23(3):e190-e194. PubMed ID: 36707275
[TBL] [Abstract][Full Text] [Related]
14. Pembrolizumab Added to Ifosfamide, Carboplatin, and Etoposide Chemotherapy for Relapsed or Refractory Classic Hodgkin Lymphoma: A Multi-institutional Phase 2 Investigator-Initiated Nonrandomized Clinical Trial.
Bryan LJ; Casulo C; Allen PB; Smith SE; Savas H; Dillehay GL; Karmali R; Pro B; Kane KL; Bazzi LA; Chmiel JS; Palmer BA; Mehta J; Gordon LI; Winter JN
JAMA Oncol; 2023 May; 9(5):683-691. PubMed ID: 36928527
[TBL] [Abstract][Full Text] [Related]
15. Ifosfamide, carboplatin and etoposide (ICE) as second-line regimen alone and in combination with regional hyperthermia is active in chemo-pre-treated advanced soft tissue sarcoma of adults.
Fiegl M; Schlemmer M; Wendtner CM; Abdel-Rahman S; Fahn W; Issels RD
Int J Hyperthermia; 2004 Sep; 20(6):661-70. PubMed ID: 15370821
[TBL] [Abstract][Full Text] [Related]
16. Ifosfamide, carboplatin, etoposide, and paclitaxel chemotherapy: a dose-escalation study.
Chang AY; Boros L; Garrow GC; Asbury RF; Hui L
Semin Oncol; 1996 Jun; 23(3 Suppl 6):74-7. PubMed ID: 8677454
[TBL] [Abstract][Full Text] [Related]
17. Ifosfamide, etoposide, cytarabine, and dexamethasone as salvage treatment followed by high-dose cyclophosphamide, melphalan, and etoposide with autologous peripheral blood stem cell transplantation for relapsed or refractory lymphomas.
Schütt P; Passon J; Ebeling P; Welt A; Müller S; Metz K; Moritz T; Seeber S; Nowrousian MR
Eur J Haematol; 2007 Feb; 78(2):93-101. PubMed ID: 17313557
[TBL] [Abstract][Full Text] [Related]
18. High-dose chemotherapy with carboplatin, etoposide and ifosfamide followed by autologous stem cell rescue in patients with relapsed or refractory malignant lymphomas: a phase I/II study.
Kleiner S; Kirsch A; Schwaner I; Kingreen D; Schwella N; Huhn D; Siegert W
Bone Marrow Transplant; 1997 Dec; 20(11):953-9. PubMed ID: 9422474
[TBL] [Abstract][Full Text] [Related]
19. [Pilot study of relapsed osteosarcoma and brain tumor with ifosfamide, carboplatin and etoposide (ICE therapy)].
Hirota T; Takeuchi M; Iwata A; Kitagawa S; Sato T; Konno K; Sawada K; Kobayashi S; Hamaguchi N; Agata H; Katano N; Fujimoto T
Gan To Kagaku Ryoho; 1998 Feb; 25(3):385-90. PubMed ID: 9492832
[TBL] [Abstract][Full Text] [Related]
20. Single-agent panobinostat for relapsed/refractory diffuse large B-cell lymphoma: clinical outcome and correlation with genomic data. A phase 2 study of the Fondazione Italiana Linfomi.
Zaja F; Salvi F; Rossi M; Sabattini E; Evangelista A; Ciccone G; Angelucci E; Gaidano G; Zanni M; Ladetto M; Chiappella A; Vitolo U; Zinzani PL; Califano C; Tucci A; Patti C; Pileri SA; Lenti V; Piccaluga PP; Cavallo F; Volpetti S; Perali G; Assouline S; Mann KK; Morin R; Alcaide M; Bushell K; Fanin R; Levis A
Leuk Lymphoma; 2018 Dec; 59(12):2904-2910. PubMed ID: 29616865
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
